Christina Cheddar Berk

Eli Lilly’s ‘diabesity’ medications are positioning it to become the first pharmaceutical company to hit $1 trillion in market cap, Morgan Stanley said.

Biotech stocks tend to outperform in the months leading up to an interest rate cut. But other factors are driving performance too.

Investors are avoiding bank stocks with high concentrations of commercial real estate. But they may also miss banks that have other risky loans.

Nvidia is a fan of Recursion Pharmaceuticals. Data expected from the company will help determine valuations for stocks using AI to discover new drugs.

Sticky inflation has produced savvy consumers, who are very deliberate about where they spend their money. That’s an advantage for some retailers.

Novo Nordisk saw price pressure for its GLP-1 drugs Ozempic and Wegovy. Investors want to know how Eli Lilly's Zepbound performed.

"Investors were nervous going in and this print would come as a huge relief," said Mohit Bansal, an analyst at Wells Fargo.

Month after month of soaring prices has wreaked havoc on household finances.These retailers with saavy store brands stand to benefit.

Recursion gets FDA approval to begin phase 1 trials of AI-discovered cancer treatment

Frenzied shopping on Black Friday will prove make-or-break for stores, and dividing lines will distinguish between the winners and losers in the retail sector.